Podcast
MSL Talk: Tom Caravela, Josh Corriveau
Life After Medical Affairs: From MSL to M & A
Summary
In this episode, Steve St. Onge shares his unique journey from traditional MSL roles to business development at Paratek. He discusses his background, transition to industry, and involvement in nontraditional MSL work. Steve delves into the challenges faced during his shift to business development and highlights essential skills for success in this area. The conversation also touches on overcoming the glass ceiling in medical affairs and leveraging medical affairs expertise in business roles. Steve offers valuable advice for MSLs considering a move into M&A or business development, emphasizing the importance of company research and utilizing LinkedIn for career advancement.
This episode features Steve St. Onge, Sr Director Business Development at Paratek discusses his career path from Medical Affairs to Business Development (M and A) and how he got there
We discuss….
👉 How he transitioned from Medical Affairs to M and A
👉 What his role in Business Development and M and A entails
👉 The difference between Corporate Development and Business Development
👉 Why LinkedIn can be an MSLs worst enemy
👉 The “glass ceiling” in Medical Affairs
👉 Why you need to learn the DNA of a company
St. Onge, MSL to Business Development, Paratek career transition, overcoming glass ceiling in medical affairs, LinkedIn for career advancement
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Josh Corriveau
Article
Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Article
Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
P.S. Mishra-Kalyani, L. Amiri Kordestani, D.R. Rivera, H. Singh, A. Ibrahim, R.A. DeClaro, Y. Shen, S. Tang, R. Sridhara, P.G. Kluetz, J. Concato, R. Pazdur, J.A. Beaver
External control arms in oncology: current use and future directions
Article
Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles